PMID- 37614844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 2229-516X (Print)
IS  - 2248-9606 (Electronic)
IS  - 2229-516X (Linking)
VI  - 13
IP  - 2
DP  - 2023 Apr-Jun
TI  - Hyperamylasemia is not Associated with Dipeptidyl Peptidase 4 Inhibitors in South 
      Indian Adults with Type 2 Diabetes Mellitus.
PG  - 113-116
LID - 10.4103/ijabmr.ijabmr_503_22 [doi]
AB  - INTRODUCTION: Although not definitive, there is small increased risk of acute 
      pancreatitis with the use of dipeptidyl peptidase 4 inhibitors (DPP4i). Hence, 
      there is an interest in the elevation of pancreatic enzymes among type 2 diabetes 
      mellitus (T2DM) patients using DPP4i. However, the studies regarding their 
      association are limited and provide conflicting results. Moreover, there are no 
      such studies among South Indian T2DM patients. Hence, we evaluated the prevalence 
      of hyperamylasemia among South Indian T2DM patients and its association with 
      DPP4i use. METHODS: This cross-sectional study was conducted at a tertiary health 
      care center from South India. Adult T2DM patients on stable doses of antidiabetic 
      medications for at least previous 3 months were included in the study. Patients 
      with other types of diabetes mellitus, gall stones, diabetic ketoacidosis, acute 
      illness, chronic kidney disease and untreated hypothyroidism were excluded from 
      the study. All participants were evaluated with glycemic parameters, serum 
      creatinine and serum amylase. Hyperamylasemia was defined as serum amylase >/=220 
      U/L. RESULTS: A total of 200 participants were included in the study among whom 
      93 patients were not on DPP4i whereas 107 were on DPP4i including 41 (38.32%) 
      each on teneligliptin and sitagliptin. Baseline characteristics including 
      glycemic measures were comparable between DPP4i users and nonusers. A total of 14 
      patients (7%) had hyperamylasemia but the prevalence of hyperamylasemia did not 
      differ between DPP4i users and nonuser (6/107 vs. 8/93, P = 0.42). CONCLUSIONS: 
      Asymptomatic hyperamylasemia is not uncommon in South Indian T2DM patients but is 
      not associated with the use of DPP4i.
CI  - Copyright: (c) 2023 International Journal of Applied and Basic Medical Research.
FAU - Sarathi, Vijaya
AU  - Sarathi V
AD  - Department of Endocrinology, Vydehi Institute of Medical Sciences and Research 
      Center, Bengaluru, Karnataka, India.
FAU - Tirupati, Sunanda
AU  - Tirupati S
AD  - Department of Endocrinology, Narayana Medical College and Hospital, Nellore, 
      Andhra Pradesh, India.
FAU - Sabinkar, Gayatri
AU  - Sabinkar G
AD  - Department of Endocrinology, Narayana Medical College and Hospital, Nellore, 
      Andhra Pradesh, India.
FAU - Mohan, Rama
AU  - Mohan R
AD  - Department of Endocrinology, Narayana Medical College and Hospital, Nellore, 
      Andhra Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20230717
PL  - India
TA  - Int J Appl Basic Med Res
JT  - International journal of applied & basic medical research
JID - 101579831
PMC - PMC10443446
OTO - NOTNLM
OT  - Dipeptidyl peptidase 4 inhibitor
OT  - hyperamylasemia
OT  - south Indians
OT  - type 2 diabetes mellitus
COIS- There are no conflicts of interest.
EDAT- 2023/08/24 06:42
MHDA- 2023/08/24 06:43
PMCR- 2023/04/01
CRDT- 2023/08/24 04:10
PHST- 2022/09/04 00:00 [received]
PHST- 2023/03/07 00:00 [revised]
PHST- 2023/05/18 00:00 [accepted]
PHST- 2023/08/24 06:43 [medline]
PHST- 2023/08/24 06:42 [pubmed]
PHST- 2023/08/24 04:10 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - IJABMR-13-113 [pii]
AID - 10.4103/ijabmr.ijabmr_503_22 [doi]
PST - ppublish
SO  - Int J Appl Basic Med Res. 2023 Apr-Jun;13(2):113-116. doi: 
      10.4103/ijabmr.ijabmr_503_22. Epub 2023 Jul 17.